ClinicalTrials.gg
Not yet recruitingNCT06573645Updated Aug 27, 2024

A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL

A Phase 3 interventional study of Rituximab in Lymphoma, Large B-Cell, Diffuse, sponsored by Xia Yi. Not yet recruiting. Open to male participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-08-27.

Sponsored by Xia Yi · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
428
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse — 20 open to participants now, 38 under way, 4 of them phase 3. Rituximab · Lymphoma, Large B-Cell, Diffuse.

Planned enrollment
11th of 211
428 · median 46
Started
2024
with 6 others
Phase 3
30 of 218
2 open now
Primary completion
2027-01
later than 19 of 37 live
Registered
209th of 218
by date

Among the 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse, this one is the 11th largest by planned enrollment of the 211 interventional ones that give a count, is one of 7 that started in 2024, is one of 30 in phase 3, reaches primary completion later than 19 of the 37 other live ones, and was the 209th registered.

Lymphoma, Large B-Cell, Diffuse

1,873 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

20 of the 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse are open now, in 6 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 265 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 176 (66%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

Comparison of MODIFIED progression-free survival (Modified-PFS) in high-dose rituximab (500mg/m²) plus CHOP versus standard-dose rituximab plus CHOP in previously untreated (TN) stage III-IV male DLBCL patients

Read the detailed description

This study is a multicenter, randomized, controlled Phase III clinical trial that primarily evaluates the modified progression-free survival (MODIFIED-PFS) in previously untreated male DLBCL patients treated with high-dose rituximab (500mg/m²) combined with the CHOP regimen compared to standard-dose rituximab combined with the CHOP regimen. After signing the informed consent and before randomization, all participants must provide sufficient tumor tissue biopsy samples for confirmation of DLBCL via central laboratory tests such as HE staining and IHC. Eligible participants are randomized in a 1:1 ratio to either the experimental group (rituximab 500 mg/m2) or the control group (rituximab 375 mg/m2) and will receive 6 cycles of R-CHOP treatment (21 days per cycle), followed by 2 additional cycles of maintenance therapy with rituximab (21 days per cycle).

03

Conditions studied

  • Lymphoma, Large B-Cell, Diffuse

Keywords

  • lymphoma
  • Diffuse large B cell lymphoma
  • High doses rituximab
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. age \<75y, male patients
  2. According to the 2017 Revised WHO Classification criteria for lymphoma, the subject was diagnosed with DLBCL
  3. According to Ann Arbor staging, patients were classified as stage III-IV patients
  4. No previous anti-tumor systemic therapy or local radiation therapy for DLBCL
  5. Expected survival ≥6 months
  6. Have sufficient coagulation function and liver and kidney function
  7. Haver sufficient bone marrow function
  8. All patients should take medically approved measures within 12 months after rituximab administration (specific circumstances should follow the listed drug label)
  9. Subjects were enrolled voluntarily, signed , and followed the experimental treatment protocol and visit plan

Key Exclusion Criteria:

  1. Subjects assessed by the investigator to be intolerant to the R-CHOP regimen and/or any drug therapy;
  2. Any previous anti-lymphoma systemic therapy or local radiation therapy
  3. Consider patients with lymphoma involving the central nervous system (CNS) or diagnosed with primary CNS lymphoma (PCNSL); The diagnosis was primary mediastinal large B-cell lymphoma (PMBL)
  4. Previously received organ transplantation or hematopoietic stem cell transplantation
  5. Had received major surgery or major trauma within 4 weeks before the first medication (or before randomization), and had participated in clinical trials of non-anti-tumor drugs or medical devices within 4 weeks
  6. Have had malignant tumors other than the indications targeted in this study in the past three years
  7. Participants with any serious and/or uncontrolled systemic disease who are determined by the investigator to be unsuitable for participation in the study
  8. Major cardiovascular disease occurred within 6 months before the first medication (or before randomization)
  9. Any conditions that affect the patient's ingestion of the drug, as well as conditions that seriously affect the absorption or pharmacokinetic parameters of the drug in the trial, including difficult to control nausea and vomiting, short bowel syndrome, etc.
  10. Subjects who received live or attenuated vaccine within 4 weeks prior to initial administration (or prior to randomization) or planned to receive during the study period or 4 weeks after the end of study treatment
  11. A hemorrhagic disease (such as von Willebrand disease or hemophilia A, hemophilia B, etc.) or according to the judgment of the investigator has a clear bleeding tendency
  12. have a serious peripheral nervous system or central nervous system disease.
  13. Warfarin or other vitamin K antagonists are required during the study
  14. There is an disease that cannot be controlled or requires treatment within 4 weeks prior to the first dose (or prior to randomization)
  15. Doxorubicin has been used in the past ≥150 mg/m2
  16. The investigator believes that the subjects have other conditions that are not suitable for participation in this experiment.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
428 participants (estimated)

Study arms

  • Experimental
    High-dose Rituximab Group

    Patients will be assigned to the trial group (rituximab 500 mg/m2) and will receive six cycles of R-CHOP (21 days per cycle), followed by two maintenance cycles of rituximab (21 days per cycle).

    Drug: Rituximab

  • Active comparator
    Standard-dose Rituximab Group

    Patients will be assigned to the control group (rituxan 375 mg/m2), the participants will receive 6 cycles R - CHOP treatment (21 d for a cycle), and the subsequent 2 cycle rituxan maintenance therapy (21 d for a cycle)

    Drug: Rituximab

Interventions

  • Patients will be randomized to receive either rituximab 500 mg/m2 or rituximab 375 mg/m2 for six cycles of R-CHOP (21 days per cycle), followed by two maintenance cycles of rituximab (21 days per cycle).

06

What researchers measure

Primary outcomes

  1. MODIFIED-PFS

    To investigate the preliminary anti-tumor efficacy

    Time frame: From the date of enrollment until the date of the first documented progression or date of death from any cause, whichever came first, assessed up to 48 months

Secondary outcomes

  1. Overall survival (OS)

    To investigate the preliminary anti-tumor efficacy

    Time frame: From the date of enrollment until the date of death from ant cause, assessed up to 48 months

  2. Complete response rate (CRR)

    To investigate the preliminary anti-tumor efficacy

    Time frame: Up to 8 cycles (each cycle is 21 days)

  3. Objective response rate (ORR)

    To investigate the preliminary anti-tumor efficacy

    Time frame: Up to 8 cycles (each cycle is 21 days)

07

Study locations

No study locations are listed for this record.

08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2024; primary completion for Jan 2027, 28 months later.

Of 73 phase 3 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 99. This study's planned 28 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2024
First posted
Aug 27, 2024
StartEst.
Aug 23, 2024
Primary completionEst.
Jan 12, 2027
CompletionEst.
Jul 12, 2027
Last update
Aug 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06573645
Lead sponsor
Xia Yi
Responsible party
Xia Yi (Director, Sun Yet-Sen University Cancer Center) — Sponsor-investigator
First posted
Aug 27, 2024
Start date
Aug 23, 2024 (estimated)
Primary completion
Jan 12, 2027 (estimated)
Completion
Jul 12, 2027 (estimated)
Last update
Aug 27, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rituximab

Start the discussion